+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Specialty Pharma Market Report 2024-2034

  • PDF Icon

    Report

  • 264 Pages
  • July 2024
  • Region: Global
  • Visiongain
  • ID: 5988337
Description Jump to:
Overall world revenue for the Specialty Pharma Market: In terms of value the market will surpass US$330 billion in 2024, the work calculates. The publisher predicts strong revenue growth through to 2034. The work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

The Specialty Pharma Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Digital Technology and AI Driving Industry Growth

In the realm of specialty pharma, the integration of digital technology and artificial intelligence (AI) promises a profound transformation. Embracing advanced IT platforms and AI-driven solutions empowers companies to enhance operational efficiency, accelerate time-to-market for biopharmaceutical products, and foster unprecedented levels of innovation. Automated workflows and real-time data analytics enable agile decision-making, enabling firms to swiftly capitalize on emerging market opportunities.

A robust IT infrastructure facilitates seamless collaboration across global teams and stakeholders, leveraging cloud-based solutions for secure data sharing and streamlined knowledge exchange. Personalized dashboards and mobile applications elevate client engagement by delivering real-time insights and actionable intelligence. This proactive approach not only enhances customer relationships but also positions companies competitively in a dynamic marketplace.

Moreover, digitalization enables predictive analytics and machine learning algorithms to optimize supply chain management and resource allocation, ensuring smoother operations and cost efficiencies. Virtual clinical trials and telemedicine platforms leverage digital advancements to improve patient recruitment, engagement, and overall trial outcomes, ultimately accelerating the delivery of innovative therapies to market.

As specialty pharma embraces digital transformation, the industry stands poised to unlock new levels of efficiency, innovation, and market expansion. Embracing these technologies not only meets current demands but also prepares companies to navigate future challenges with agility and foresight, shaping a resilient and forward-looking specialty pharma landscape.

Rising Specialty Drug Costs Likely to Challenge Industry Growth

The rising cost of specialty drugs poses a significant challenge to the growth of the specialty drugs market. These medications, often developed for complex and rare conditions, come with hefty price tags that can strain healthcare systems and patients alike. Recent examples highlight these concerns vividly. Firstly, Biogen's Alzheimer's drug, Aduhelm, priced at US$56,000 annually, sparked controversy over its affordability and potential impact on healthcare budgets. Despite its FDA approval, questions persist about whether its benefits justify the high cost.

Similarly, Eisai and Biogen's Leqembi, another Alzheimer's drug priced at $26,500 per year, faces scrutiny for its financial burden on Medicare beneficiaries and the healthcare system. The drug's cost, coupled with its modest efficacy, has raised doubts about its widespread adoption and long-term sustainability.

Moreover, the broader issue of specialty drug pricing extends beyond Alzheimer's treatments. Medications like Entresto, crucial for heart failure patients, also come at significant costs, influencing healthcare expenditure patterns and patient access. These examples underscore the broader challenge facing the specialty drugs market: balancing innovation and access with affordability. As these drugs promise breakthrough treatments for severe conditions, their high prices often limit accessibility, potentially depriving patients of life-changing therapies.

Addressing this challenge requires careful consideration of pricing strategies, reimbursement mechanisms, and policies that ensure equitable access without compromising innovation incentives. Stakeholders, including pharmaceutical companies, policymakers, and insurers, must collaborate to find sustainable solutions that promote both medical progress and patient welfare in an increasingly complex healthcare landscape.

Key Questions Answered

  • How is the Specialty Pharma market evolving?
  • What is driving and restraining the Specialty Pharma market?
  • How will each Specialty Pharma submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
  • How will the market shares for each Specialty Pharma submarket develop from 2024 to 2034?
  • What will be the main driver for the overall market from 2024 to 2034?
  • Will leading Specialty Pharma markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the Specialty Pharma projects for these leading companies?
  • How will the industry evolve during the period between 2024 and 2034? What are the implications of Specialty Pharma projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the Specialty Pharma market?
  • Where is the Specialty Pharma market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Specialty Pharma market today, and over the next 10 years:

  • This 264-page report provides 102 tables and 171 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2034 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2034, the new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Specialty Pharma prices and recent developments.

Segments Covered in the Report

Route of Administration

  • Oral
  • Parenteral
  • Rectal

Distribution Channel

  • Hospitals
  • Retail Pharmacies
  • Specialty Pharmacies

Therapeutics

  • Oncology
  • Cervical Cancer
  • Prostate Cancer
  • Others
  • Immunology
  • Arthritis
  • Crohn's Disease
  • Ulcerative Colitis
  • Others
  • Diabetes
  • Type 2 Diabetes (Non-insulin)
  • Type 1 Diabetes & Others
  • Cardiovascular Disease
  • Hypertension
  • Hyperlipidemia
  • Others
  • Respiratory
  • Asthma
  • COPD
  • Others
  • CNS
  • Neurovascular Diseases
  • Neurodegenerative Diseases
  • Mental Health
  • Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA
The report also includes profiles for some of the leading companies in the Specialty Pharma Market, with a focus on this segment of these companies’ operations.

Leading companies profiled in the report

  • AbbVie
  • Amgen Inc.
  • AstraZeneca
  • CVS Health
  • Endo, Inc.
  • Humana
  • Johnson & Johnson
  • Lumicera
  • Soleo Health
  • Sun Pharmaceutical Industries Ltd.
  • The Cigna Group
  • Teva Pharmaceutical Industries Ltd.
  • UnitedHealth Group (Optum, Inc.)
  • Viatris Inc.
  • Walgreens Boots Alliance, Inc.

How will the Specialty Pharma Market report help you?

In summary, the 260+ page report provides you with the following knowledge:
  • Revenue forecasts to 2034 for Specialty Pharma Market Market, with forecasts for route of administration, therapeutics, and distribution channel each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2034 for five regional and 20 key national markets - See forecasts for the Specialty Pharma Market market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Specialty Pharma Market.
Find quantitative and qualitative analyses with independent predictions. Receive information that only this report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. This study is for everybody needing commercial analyses for the Specialty Pharma Market, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Specialty Pharma Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About the Publisher
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Specialty Pharmaceutical Market Surges in Global Spending Landscape
3.3.1.2 Immunology Market Surge Fuels Specialty Pharmaceuticals Growth
3.3.1.3 Expanding Oncology Drug Demand Shapes Specialty Pharma Market Growth
3.3.2 Market Restraining Factors
3.3.2.1 Challenges of Rising Specialty Drug Costs in Healthcare
3.3.2.2 The Impact of High Drug Costs on Insurance and Specialty Markets
3.3.3 Market Opportunities
3.3.3.1 Advanced Therapies and Innovation Fuelling Specialty Pharma Market Growth
3.3.3.2 Specialty Pharma Seizes Growth Opportunity in Chronic and Rare Diseases
3.4 Supply Chain Analysis
3.5 Regulatory Framework
3.6 Emerging Markets and Megatrends
3.7 Porter’s Five Forces Analysis
3.7.1 Bargaining Power of Suppliers
3.7.2 Bargaining Power of Buyers
3.7.3 Competitive Rivalry
3.7.4 Threat of Substitutes
3.7.5 Threat of New Entrants
3.8 PEST Analysis
4 Specialty Pharma Market Analysis Route of Administration
4.1 Key Findings
4.2 Route of Administration Segment: Market Attractiveness Index
4.3 Specialty Pharma Market Size Estimation and Forecast by Route of Administration
4.4 Oral
4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 Parenteral
4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
4.5.2 Market Share by Region, 2024 & 2034 (%)
4.6 Rectal
4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
4.6.2 Market Share by Region, 2024 & 2034 (%)
5 Specialty Pharma Market Analysis Distribution Channel
5.1 Key Findings
5.2 Distribution Channel Segment: Market Attractiveness Index
5.3 Specialty Pharma Market Size Estimation and Forecast by Distribution Channel
5.4 Hospitals
5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Retail Pharmacies
5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Specialty Pharmacies
5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
5.6.2 Market Share by Region, 2024 & 2034 (%)
6 Specialty Pharma Market Analysis by Therapeutics
6.1 Key Findings
6.2 Therapeutics Segment: Market Attractiveness Index
6.3 Specialty Pharma Market Size Estimation and Forecast by Therapeutics
6.4 Oncology
6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
6.4.2 Market Share by Region, 2024 & 2034 (%)
6.4.3 Oncology Market Size by Type
6.4.3.1 Cervical Cancer
6.4.3.2 Prostate Cancer
6.4.3.3 Others
6.5 Immunology
6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
6.5.2 Market Share by Region, 2024 & 2034 (%)
6.5.3 Immunology Market Size by Type
6.5.3.1 Arthritis
6.5.3.2 Crohn's Disease
6.5.3.3 Ulcerative Colitis
6.5.3.4 Others
6.6 Diabetes
6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
6.6.2 Market Share by Region, 2024 & 2034 (%)
6.6.3 Diabetes Market Size by Type
6.6.3.1 Type 2 Diabetes (Non-insulin)
6.6.3.2 Type 1 Diabetes & Others
6.7 Cardiovascular Disease
6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
6.7.2 Market Share by Region, 2024 & 2034 (%)
6.7.3 Cardiovascular Disease Market Size by Type
6.7.3.1 Hypertension
6.7.3.2 Hyperlipidaemia
6.7.3.3 Others
6.8 Respiratory
6.8.1 Market Size by Region, 2024-2034 (US$ Billion)
6.8.2 Market Share by Region, 2024 & 2034 (%)
6.8.3 Respiratory Market Size by Type
6.8.3.1 Asthma
6.8.3.2 COPD
6.8.3.3 Others
6.9 CNS
6.9.1 Market Size by Region, 2024-2034 (US$ Billion)
6.9.2 Market Share by Region, 2024 & 2034 (%)
6.9.3 CNS Market Size by Type
6.9.3.1 Neurovascular Diseases
6.9.3.2 Neurodegenerative Diseases
6.9.3.3 Mental Health
6.10 Others
6.10.1 Market Size by Region, 2024-2034 (US$ Billion)
6.10.2 Market Share by Region, 2024 & 2034 (%)
7 Specialty Pharma Market Analysis by Region
7.1 Key Findings
7.2 Regional Market Size Estimation and Forecast
8 North America Specialty Pharma Market Analysis
8.1 Key Findings
8.2 North America Specialty Pharma Market Attractiveness Index
8.3 North America Specialty Pharma Market by Country, 2024, 2029 & 2034 (US$ Billion)
8.4 North America Specialty Pharma Market Size Estimation and Forecast by Country
8.5 North America Specialty Pharma Market Size Estimation and Forecast by Route of Administration
8.6 North America Specialty Pharma Market Size Estimation and Forecast by Distribution Channel
8.7 North America Specialty Pharma Market Size Estimation and Forecast by Therapeutics
8.8 U.S. Specialty Pharma Market Analysis
8.9 Canada Specialty Pharma Market Analysis
9 Europe Specialty Pharma Market Analysis
9.1 Key Findings
9.2 Europe Specialty Pharma Market Attractiveness Index
9.3 Europe Specialty Pharma Market by Country, 2024, 2029 & 2034 (US$ Billion)
9.4 Europe Specialty Pharma Market Size Estimation and Forecast by Country
9.5 Europe Specialty Pharma Market Size Estimation and Forecast by Route of Administration
9.6 Europe Specialty Pharma Market Size Estimation and Forecast by Distribution Channel
9.7 Europe Specialty Pharma Market Size Estimation and Forecast by Therapeutics
9.8 Germany Specialty Pharma Market Analysis
9.9 France Specialty Pharma Market Analysis
9.10 UK Specialty Pharma Market Analysis
9.11 Italy Specialty Pharma Market Analysis
9.12 Spain Specialty Pharma Market Analysis
9.13 Rest of Europe Specialty Pharma Market Analysis
10 Asia Pacific Specialty Pharma Market Analysis
10.1 Key Findings
10.2 Asia Pacific Specialty Pharma Market Attractiveness Index
10.3 Asia Pacific Specialty Pharma Market by Country, 2024, 2029 & 2034 (US$ Billion)
10.4 Asia Pacific Specialty Pharma Market Size Estimation and Forecast by Country
10.5 Asia Pacific Specialty Pharma Market Size Estimation and Forecast by Route of Administration
10.6 Asia Pacific Specialty Pharma Market Size Estimation and Forecast by Distribution Channel
10.7 Asia Pacific Specialty Pharma Market Size Estimation and Forecast by Therapeutics
10.8 Japan Specialty Pharma Market Analysis
10.9 China Specialty Pharma Market Analysis
10.10 India Specialty Pharma Market Analysis
10.11 Australia Specialty Pharma Market Analysis
10.12 South Korea Specialty Pharma Market Analysis
10.13 Rest of Asia Pacific Specialty Pharma Market Analysis
11 Latin America Specialty Pharma Market Analysis
11.1 Key Findings
11.2 Latin America Specialty Pharma Market Attractiveness Index
11.3 Latin America Specialty Pharma Market by Country, 2024, 2029 & 2034 (US$ Billion)
11.4 Latin America Specialty Pharma Market Size Estimation and Forecast by Country
11.5 Latin America Specialty Pharma Market Size Estimation and Forecast by Route of Administration
11.6 Latin America Specialty Pharma Market Size Estimation and Forecast by Distribution Channel
11.7 Latin America Specialty Pharma Market Size Estimation and Forecast by Therapeutics
11.8 Brazil Specialty Pharma Market Analysis
11.9 Mexico Specialty Pharma Market Analysis
11.10 Rest of Latin America Specialty Pharma Market Analysis
12 MEA Specialty Pharma Market Analysis
12.1 Key Findings
12.2 MEA Specialty Pharma Market Attractiveness Index
12.3 MEA Specialty Pharma Market by Country, 2024, 2029 & 2034 (US$ Billion)
12.4 MEA Specialty Pharma Market Size Estimation and Forecast by Country
12.5 MEA Specialty Pharma Market Size Estimation and Forecast by Route of Administration
12.6 MEA Specialty Pharma Market Size Estimation and Forecast by Distribution Channel
12.7 MEA Specialty Pharma Market Size Estimation and Forecast by Therapeutics
12.8 GCC Specialty Pharma Market Analysis
12.9 South Africa Specialty Pharma Market Analysis
12.10 Rest of MEA Specialty Pharma Market Analysis
13 Company Profiles
13.1 Competitive Landscape, 2023
13.2 Strategic Outlook
13.3 CVS Health
13.3.1 Company Snapshot
13.3.2 Company Overview
13.3.3 Financial Analysis
13.3.3.1 Net Revenue, 2019-2023
13.3.3.2 Business Segment Market Shares, 2023
13.3.4 Product Benchmarking
13.3.5 SWOT Analysis
13.4 The Cigna Group
13.4.1 Company Snapshot
13.4.2 Company Overview
13.4.3 Financial Analysis
13.4.3.1 Net Revenue, 2019-2023
13.4.3.2 Business Segment Market Shares, 2023
13.4.4 Product Benchmarking
13.4.5 SWOT Analysis
13.5 UnitedHealth Group (Optum, Inc.)
13.5.1 Company Snapshot
13.5.2 Company Overview
13.5.3 Financial Analysis
13.5.3.1 Net Revenue, 2019-2023
13.5.3.2 Business Segment Market Shares, 2023
13.5.4 Product Benchmarking
13.5.5 Strategic Outlook
13.5.6 SWOT Analysis
13.6 Walgreens Boots Alliance, Inc.
13.6.1 Company Snapshot
13.6.2 Company Overview
13.6.3 Financial Analysis
13.6.3.1 Net Revenue, 2019-2023
13.6.3.2 Regional Market Shares, 2023
13.6.3.3 Business Segment Market Shares, 2023
13.6.4 Product Benchmarking
13.6.5 Strategic Outlook
13.6.6 SWOT Analysis
13.7 Humana
13.7.1 Company Snapshot
13.7.2 Company Overview
13.7.3 Financial Analysis
13.7.3.1 Net Revenue, 2019-2023
13.7.3.2 Business Segment Market Shares, 2023
13.7.4 Product Benchmarking
13.8 Teva Pharmaceutical Industries Ltd.
13.8.1 Company Snapshot
13.8.2 Company Overview
13.8.3 Financial Analysis
13.8.3.1 Net Revenue, 2019-2023
13.8.3.2 R&D, 2019-2023
13.8.3.3 Regional Market Shares, 2023
13.8.4 Product Benchmarking
13.8.5 Strategic Outlook
13.9 Endo, Inc.
13.9.1 Company Snapshot
13.9.2 Company Overview
13.9.3 Product Benchmarking
13.10 AbbVie
13.10.1 Company Snapshot
13.10.2 Company Overview
13.10.3 Financial Analysis
13.10.3.1 Net Revenue, 2019-2023
13.10.3.2 R&D, 2019-2023
13.10.3.3 Regional Market Shares, 2023
13.10.3.4 Business Segment Market Shares, 2023
13.10.4 Product Benchmarking
13.10.5 Strategic Outlook
13.11 AstraZeneca
13.11.1 Company Snapshot
13.11.2 Company Overview
13.11.3 Financial Analysis
13.11.3.1 Net Revenue, 2019-2023
13.11.3.2 R&D, 2019-2023
13.11.3.3 Regional Market Shares, 2023
13.11.4 Product Benchmarking
13.12 Amgen Inc.
13.12.1 Company Snapshot
13.12.2 Company Overview
13.12.3 Financial Analysis
13.12.3.1 Net Revenue, 2019-2023
13.12.3.2 R&D, 2019-2023
13.12.3.3 Regional Market Shares, 2023
13.12.4 Product Benchmarking
13.12.5 Strategic Outlook
13.13 Viatris Inc.
13.13.1 Company Snapshot
13.13.2 Company Overview
13.13.3 Financial Analysis
13.13.3.1 Net Revenue, 2019-2023
13.13.3.2 R&D, 2019-2023
13.13.3.3 Regional Market Shares, 2023
13.13.4 Product Benchmarking
13.14 Johnson & Johnson
13.14.1 Company Snapshot
13.14.2 Company Overview
13.14.3 Financial Analysis
13.14.3.1 Net Revenue, 2019-2023
13.14.3.2 R&D, 2019-2023
13.14.3.3 Regional Market Shares, 2023
13.14.3.4 Business Segment Market Shares, 2023
13.14.4 Product Benchmarking
13.15 Sun Pharmaceutical Industries Ltd.
13.15.1 Company Snapshot
13.15.2 Company Overview
13.15.3 Financial Analysis
13.15.3.1 Net Revenue, 2020-2024
13.15.4 Product Benchmarking
13.15.5 Strategic Outlook
13.16 Soleo Health
13.16.1 Company Snapshot
13.16.2 Company Overview
13.16.3 Product Benchmarking
13.16.4 Strategic Outlook
13.17 Lumicera
13.17.1 Company Snapshot
13.17.2 Company Overview
13.17.3 Product Benchmarking
14 Conclusion and Recommendations
14.1 Concluding Remarks
14.2 Recommendations for Market Players
List of Tables
Table 1 Specialty Pharma Market Snapshot, 2024 & 2034 (US$ Billion, CAGR %)
Table 2 Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 3 Oral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 4 Parenteral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 5 Rectal Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 6 Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 7 Hospitals Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 8 Retail Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 9 Specialty Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 10 Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 11 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 12 Oncology Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 13 Immunology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 14 Immunology Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 15 Diabetes Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 16 Diabetes Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 17 Cardiovascular Disease Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 18 Cardiovascular Disease Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 19 Respiratory Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 20 Respiratory Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 21 CNS Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 22 CNS Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 23 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 24 Specialty Pharma Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 25 North America Specialty Pharma Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 26 North America Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 27 North America Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 28 North America Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 29 U.S. Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 30 Canada Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 31 Europe Specialty Pharma Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 32 Europe Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 33 Europe Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 34 Europe Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 35 Germany Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 36 France Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 37 UK Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 38 Italy Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 39 Spain Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 40 Rest of Europe Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 41 Asia Pacific Specialty Pharma Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 42 Asia Pacific Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 43 Asia Pacific Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 44 Asia Pacific Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 45 Japan Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 46 China Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 47 India Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 48 Australia Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 49 South Korea Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 50 Rest of Asia Pacific Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 51 Latin America Specialty Pharma Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 52 Latin America Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 53 Latin America Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 54 Latin America Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 55 Brazil Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 56 Mexico Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 57 Rest of Latin America Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 58 MEA Specialty Pharma Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 59 MEA Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 60 MEA Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 61 MEA Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 62 GCC Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 63 South Africa Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 64 Rest of MEA Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 65 Strategic Outlook
Table 66 CVS Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 67 CVS Health: Product Benchmarking
Table 68 The Cigna Group: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 69 The Cigna Group: Product Benchmarking
Table 70 UnitedHealth Group. (Optum, Inc.): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 71 UnitedHealth Group. (Optum, Inc.): Product Benchmarking
Table 72 UnitedHealth Group. (Optum, Inc.): Strategic Outlook
Table 73 Walgreens Boots Alliance, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 74 Walgreens Boots Alliance, Inc.: Product Benchmarking
Table 75 Walgreens Boots Alliance, Inc.: Strategic Outlook
Table 76 Humana: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 77 Humana: Product Benchmarking
Table 78 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
Table 80 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
Table 81 Endo, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 Endo, Inc.: Product Benchmarking
Table 83 AbbVie: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 AbbVie: Product Benchmarking
Table 85 AbbVie: Strategic Outlook
Table 86 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 AstraZeneca: Product Benchmarking
Table 88 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 Amgen Inc.: Product Benchmarking
Table 90 Amgen Inc.: Strategic Outlook
Table 91 Viatris Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 92 Viatris Inc.: Product Benchmarking
Table 93 Johnson & Johnson: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Johnson & Johnson: Product Benchmarking
Table 95 Sun Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 Sun Pharmaceutical Industries Ltd.: Product Benchmarking
Table 97 Sun Pharmaceutical Industries Ltd.: Strategic Outlook
Table 98 Soleo Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Soleo Health: Product Benchmarking
Table 100 Soleo Health: Strategic Outlook
Table 101 Lumicera: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Lumicera: Product Benchmarking
List of Figures
Figure 1 Specialty Pharma Market Segmentation
Figure 2 Specialty Pharma Market by Route of Administration: Market Attractiveness Index
Figure 3 Specialty Pharma Market by Distribution Channel: Market Attractiveness Index
Figure 4 Specialty Pharma Market by Therapeutics: Market Attractiveness Index
Figure 5 Specialty Pharma Market Attractiveness Index by Region
Figure 6 Specialty Pharma Market: Market Dynamics
Figure 7 Specialty Pharma Market: Impact Analysis
Figure 8 Share of Specialty Products in Global Pharmaceutical Spending
Figure 9 Global Pharmaceutical Spending, US$ Billion (2013 - 2027)
Figure 10 Global New Incidences of New Cancer Cases per 100,000 People
Figure 11 Global Cancer Cases by Country, 2022
Figure 12 Specialty Pharma Industry: Supply Chain Analysis
Figure 13 Specialty Pharma Market: Porter’s Five Forces Analysis
Figure 14 Specialty Pharma Market: PEST Analysis
Figure 15 Specialty Pharma Market Route of Administration: Market Attractiveness Index
Figure 16 Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 17 Specialty Pharma Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 18 Oral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 19 Oral Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 20 Parenteral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 21 Parenteral Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 22 Rectal Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 23 Rectal Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 24 Specialty Pharma Market Distribution Channel: Market Attractiveness Index
Figure 25 Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 26 Specialty Pharma Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 27 Hospitals Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 28 Hospitals Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 29 Retail Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 30 Retail Pharmacies Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 31 Specialty Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 32 Specialty Pharmacies Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 33 Specialty Pharma Market by Therapeutics: Market Attractiveness Index
Figure 34 Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %)
Figure 35 Specialty Pharma Market Share Forecast by Therapeutics, 2024, 2029, 2034 (%)
Figure 36 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 37 Oncology Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 38 Oncology Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 39 Oncology Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 40 Immunology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 41 Immunology Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 42 Immunology Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 43 Immunology Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 44 Diabetes Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 45 Diabetes Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 46 Diabetes Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 47 Diabetes Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 48 Cardiovascular Disease Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 49 Cardiovascular Disease Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 50 Cardiovascular Diseases Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 51 Cardiovascular Diseases Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 52 Respiratory Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 53 Respiratory Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 54 Respiratory Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 55 Respiratory Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 56 CNS Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 57 CNS Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 58 CNS Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 59 CNS Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 60 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 61 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 62 Specialty Pharma Market Forecast by Region 2024 and 2034 (Revenue, CAGR %)
Figure 63 Specialty Pharma Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 64 Specialty Pharma Market by Region, 2024-2034 (US$ Billion, AGR %)
Figure 65 North America Specialty Pharma Market Attractiveness Index
Figure 66 North America Specialty Pharma Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 67 North America Specialty Pharma Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 68 North America Specialty Pharma Market Share Forecast by Country, 2024 & 2034 (%)
Figure 69 North America Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 70 North America Specialty Pharma Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 71 North America Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 72 North America Specialty Pharma Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 73 North America Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %)
Figure 74 North America Specialty Pharma Market Share Forecast by Therapeutics, 2024 & 2034 (%)
Figure 75 U.S. Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 76 Canada Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 77 Europe Specialty Pharma Market Attractiveness Index
Figure 78 Europe Specialty Pharma Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 79 Europe Specialty Pharma Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 80 Europe Specialty Pharma Market Share Forecast by Country, 2024 & 2034 (%)
Figure 81 Europe Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 82 Europe Specialty Pharma Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 83 Europe Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 84 Europe Specialty Pharma Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 85 Europe Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %)
Figure 86 Europe Specialty Pharma Market Share Forecast by Therapeutics, 2024 & 2034 (%)
Figure 87 Germany Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 88 France Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 89 UK Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 90 Italy Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 91 Spain Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 92 Rest of Europe Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 93 Asia Pacific Specialty Pharma Market Attractiveness Index
Figure 94 Asia Pacific Specialty Pharma Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 95 Asia Pacific Specialty Pharma Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 96 Asia Pacific Specialty Pharma Market Share Forecast by Country, 2024 & 2034 (%)
Figure 97 Asia Pacific Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 98 Asia Pacific Specialty Pharma Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 99 Asia Pacific Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 100 Asia Pacific Specialty Pharma Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 101 Asia Pacific Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %)
Figure 102 Asia Pacific Specialty Pharma Market Share Forecast by Therapeutics, 2024 & 2034 (%)
Figure 103 Japan Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 104 China Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 105 India Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 106 Australia Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 107 South Korea Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 108 Rest of Asia Pacific Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 109 Latin America Specialty Pharma Market Attractiveness Index
Figure 110 Latin America Specialty Pharma Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 111 Latin America Specialty Pharma Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 112 Latin America Specialty Pharma Market Share Forecast by Country, 2024 & 2034 (%)
Figure 113 Latin America Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 114 Latin America Specialty Pharma Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 115 Latin America Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 116 Latin America Specialty Pharma Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 117 Latin America Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %)
Figure 118 Latin America Specialty Pharma Market Share Forecast by Therapeutics, 2024 & 2034 (%)
Figure 119 Brazil Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 120 Mexico Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 121 Rest of Latin America Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 122 MEA Specialty Pharma Market Attractiveness Index
Figure 123 MEA Specialty Pharma Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 124 MEA Specialty Pharma Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 125 MEA Specialty Pharma Market Share Forecast by Country, 2024 & 2034 (%)
Figure 126 MEA Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 127 MEA Specialty Pharma Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 128 MEA Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 129 MEA Specialty Pharma Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 130 MEA Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %)
Figure 131 MEA Specialty Pharma Market Share Forecast by Therapeutics, 2024 & 2034 (%)
Figure 132 GCC Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 133 South Africa Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 134 Rest of MEA Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 135 Specialty Pharma Market: Company Share/Ranking, 2023
Figure 136 CVS Health: Net Revenue, 2019-2023 (US$ Billion, AGR %)
Figure 137 CVS Health: Business Segment Market Shares, 2023
Figure 138 CVS Health: SWOT Analysis
Figure 139 The Cigna Group: Net Revenue, 2019-2023 (US$ Billion, AGR %)
Figure 140 The Cigna Group: Business Segment Market Shares, 2023
Figure 141 The Cigna Group: SWOT Analysis
Figure 142 UnitedHealth Group. (Optum, Inc.): Net Revenue, 2019-2023 (US$ Billion, AGR %)
Figure 143 UnitedHealth Group. (Optum, Inc.): Business Segment Market Shares, 2023
Figure 144 UnitedHealth Group. (Optum, Inc.): SWOT Analysis
Figure 145 Walgreens Boots Alliance, Inc.: Net Revenue, 2019-2023 (US$ Billion, AGR %)
Figure 146 Walgreens Boots Alliance, Inc.: Regional Market Shares, 2023
Figure 147 Walgreens Boots Alliance, Inc.: Business Segment Market Shares, 2023
Figure 148 Walgreens Boots Alliance, Inc.: SWOT Analysis
Figure 149 Humana: Net Revenue, 2019-2023 (US$ Billion, AGR %)
Figure 150 Humana: Business Segment Market Shares, 2023
Figure 151 Teva Pharmaceutical Industries Ltd.: Net Revenue, 2019-2023 (US$ Billion, AGR %)
Figure 152 Teva Pharmaceutical Industries Ltd.: R&D, 2019-2023 (US$ Billion, AGR %)
Figure 153 Teva Pharmaceutical Industries Ltd.: Regional Market Shares, 2023
Figure 154 AbbVie: Net Revenue, 2019-2023 (US$ Billion, AGR %)
Figure 155 AbbVie: R&D, 2019-2023 (US$ Billion, AGR %)
Figure 156 AbbVie: Regional Market Shares, 2023
Figure 157 AbbVie: Business Segment Market Shares, 2023
Figure 158 AstraZeneca: Net Revenue, 2019-2023 (US$ Billion, AGR %)
Figure 159 AstraZeneca: R&D, 2019-2023 (US$ Billion, AGR %)
Figure 160 AstraZeneca: Regional Market Shares, 2023
Figure 161 Amgen Inc.: Net Revenue, 2019-2023 (US$ Billion, AGR %)
Figure 162 Amgen Inc.: R&D, 2019-2023 (US$ Billion, AGR %)
Figure 163 Amgen Inc.: Regional Market Shares, 2023
Figure 164 Viatris Inc.: Net Revenue, 2019-2023 (US$ Billion, AGR %)
Figure 165 Viatris Inc.: R&D, 2019-2023 (US$ Billion, AGR %)
Figure 166 Viatris Inc.: Regional Market Shares, 2023
Figure 167 Johnson & Johnson: Net Revenue, 2019-2023 (US$ Billion, AGR %)
Figure 168 Johnson & Johnson: R&D, 2019-2023 (US$ Billion, AGR %)
Figure 169 Johnson & Johnson: Regional Market Shares, 2023
Figure 170 Johnson & Johnson: Business Segment Market Shares, 2023
Figure 171 Sun Pharmaceutical Industries Ltd.: Net Revenue, 2020-2024 (US$ Billion, AGR %)

Companies Mentioned

  • AbbVie
  • Amgen Inc.
  • AstraZeneca
  • CVS Health
  • Endo, Inc.
  • Humana
  • Johnson & Johnson
  • Lumicera
  • Soleo Health
  • Sun Pharmaceutical Industries Ltd.
  • The Cigna Group
  • Teva Pharmaceutical Industries Ltd.
  • UnitedHealth Group (Optum, Inc.)
  • Viatris Inc.
  • Walgreens Boots Alliance, Inc.
  • Alvotech
  • Asieris Pharmaceuticals
  • Biocon Ltd.
  • BioScript Solutions
  • Bristol-Myers Squibb
  • Celltrion
  • Chugai Pharmaceutical Co., Ltd
  • Cipla
  • Dendreon Pharmaceuticals LLC
  • Evotec SE
  • Genentech
  • Grant Hill
  • Green Cross Corporation
  • GSK Plc
  • Gulf Pharmaceutical Industries
  • Hanmi Pharmaceutical
  • Hikma Pharmaceuticals
  • Janssen Biotech
  • Julphar
  • Novartis
  • Regeneron Pharmaceuticals, Inc.
  • Roche Group
  • Samsung Bioepis
  • Sanofi
  • Shire Pharmaceuticals
  • Sierra Oncology Inc
  • Specialised Therapeutics Australia
  • SPIMACO
  • Yuhan Corporation
  • Brazilian Health Regulatory Agency (ANVISA)
  • European Medicines Agency (EMA)
  • European Pharmacopoeia
  • Food and Drug Administration (FDA)
  • International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)
  • International Organization for Standardization (ISO)
  • Mexican Association of Gastroenterology
  • U.S. Department of Health and Human Services
  • United States Pharmacopeia (USP)

Related Topics

Related Reports

Pharma Wholesale and Distribution Market Report 2024-2034 - Product Image

Pharma Wholesale and Distribution Market Report 2024-2034

  • Report
  • 304 Pages
  • Global
From
Clinical Trial Supply and Logistics Market for Pharma 2024-2034 - Product Image

Clinical Trial Supply and Logistics Market for Pharma 2024-2034

  • Report
  • 275 Pages
  • Global
From
Digital Pills Market by Product Type, by Indication, by Distribution Channel, and by Region - Product Image

Digital Pills Market by Product Type, by Indication, by Distribution Channel, and by Region

  • Report
  • 200 Pages
  • Global
From
Specialty Pharmaceuticals - Global Strategic Business Report - Product Image

Specialty Pharmaceuticals - Global Strategic Business Report

  • Report
  • 291 Pages
  • Global
From
Pharma Grade Glycine Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Pharma Grade Glycine Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 90 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.